Clinical trial NCT05945485: A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
Official title: A Phase 1, Comparator-Controlled, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Influenza
Keywords: Comparator-Controlled
Dose-Escalation
Healthy Adults
Immunogenicity
Influenza
mRNA-LNP Vaccine
Randomized
Safety
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor class: NIH
First posted: 2023-07-14
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: PREVENTION

Brief summary: This is a Phase 1, single-site, comparator-controlled, dosage-escalating study of an intramuscularly administered mRNA-LNP vaccine encoding for DCVC H1 HA in up to 50 adult volunteers aged 18 to 49 years, inclusive. This study is designed to assess the safety and immunogenicity of two doses of DCVC H1 HA mRNA vaccine administered 28 days apart. Eligible participants will be sequentially enrolled into dosage escalation groups (10 mcg, 25 mcg, and 50 mcg). A separate group of 10 participants will receive one dose of the licensed quadrivalent influenza vaccine (IIV4). Enrollment of participants into the IIV4 group is limited to when the vaccine is available for a given year. Concurrent enrollment of the IIV4 group and any pre-specified study product group or groups may present logistical challenges due to the availability of the IIV4 vaccine and may preclude enrollment of all study participants prior to the subsequent off-season. Participants receiving IIV4 will be followed for safety but only their immune responses will be compared to those of participants receiving DCVC H1 HA mRNA vaccine. Dosing of DCVC H1 HA mRNA vaccine will commence at the lowest dose (10 mcg) and only escalate to the next highest dose if safety concerns are not identified.

For each DCVC H1 HA mRNA vaccine dosing group, the first two participants enrolled will be considered the sentinel subgroup. After the two participants in the Low Dose sentinel subgroup are enrolled and given their first vaccination, enrollment and subsequent vaccinations in that dosing group will then be stopped until Day 3. This review will be conducted by a Safety Review Committee (SRC). If no halting criteria are met, the SRC will allow administration of the second dose for the sentinel subgroup and continued enrollment of the remaining 8 Low Dose Group participants (expanded subgroup) to complete enrollment of 10 participants. In order for a timely receipt of a second dose of study product on Day 29, SRC review and approval must occur prior to Study Day 28 for the first sentinel participant in the Low Dose Group. After the Low Dose Group enrollment is completed and both doses have been administered, enrollment will be stopped pending SRC review. After all participants in the Low Dose Group have completed the Day 36 visit, the SRC will review the clinical laboratory, reactogenicity, and adverse event information through the Day 36 visit for all Low Dose Group participants that received two doses. Approval by the SRC will allow dose escalation and initiation of enrollment of the Medium Dose Group sentinel subgroup. The Medium and High Dose sentinel and expanded groups will be enrolled as described above for the Low Dose sentinel and expanded groups, respectively, with the High Dose expanded subgroup enrolling up to 18 individuals.

The primary objective of this study is to assess the safety of two doses of DCVC H1 HA mRNA Vaccine administered intramuscularly in healthy adults (18-49 yrs) at dosage levels of 10 mcg, 25 mcg, and 50 mcg.

Detailed description: This is a Phase 1, single-site, comparator-controlled, dosage-escalating study of an intramuscularly administered mRNA-LNP vaccine encoding for DCVC H1 HA in up to 50 adult volunteers aged 18 to 49 years, inclusive. This study is designed to assess the safety and immunogenicity of two doses of DCVC H1 HA mRNA vaccine administered 28 days apart. Eligible participants will be sequentially enrolled into dosage escalation groups (10 mcg, 25 mcg, and 50 mcg). A separate group of 10 participants will receive one dose of the licensed quadrivalent influenza vaccine (IIV4). Enrollment of participants into the IIV4 group is limited to when the vaccine is available for a given year. Concurrent enrollment of the IIV4 group and any pre-specified study product group or groups may present logistical challenges due to the availability of the IIV4 vaccine and may preclude enrollment of all study participants prior to the subsequent off-season. Participants receiving IIV4 will be followed for safety but only their immune responses will be compared to those of participants receiving DCVC H1 HA mRNA vaccine. Dosing of DCVC H1 HA mRNA vaccine will commence at the lowest dose (10 mcg) and only escalate to the next highest dose if safety concerns are not identified.

For each DCVC H1 HA mRNA vaccine dosing group, the first two participants enrolled will be considered the sentinel subgroup. After the two participants in the Low Dose sentinel subgroup are enrolled and given their first vaccination, enrollment and subsequent vaccinations in that dosing group will then be stopped until Day 3. This review will be conducted by a Safety Review Committee (SRC). If no halting criteria are met, the SRC will allow administration of the second dose for the sentinel subgroup and continued enrollment of the remaining 8 Low Dose Group participants (expanded subgroup) to complete enrollment of 10 participants. In order for a timely receipt of a second dose of study product on Day 29, SRC review and approval must occur prior to Study Day 28 for the first sentinel participant in the Low Dose Group. After the Low Dose Group enrollment is completed and both doses have been administered, enrollment will be stopped pending SRC review. After all participants in the Low Dose Group have completed the Day 36 visit, the SRC will review the clinical laboratory, reactogenicity, and adverse event information through the Day 36 visit for all Low Dose Group participants that received two doses. Approval by the SRC will allow dose escalation and initiation of enrollment of the Medium Dose Group sentinel subgroup. The Medium and High Dose sentinel and expanded groups will be enrolled as described above for the Low Dose sentinel and expanded groups, respectively, with the High Dose expanded subgroup enrolling up to 18 individuals.

The primary objective of this study is to assess the safety of two doses of DCVC H1 HA mRNA Vaccine administered intramuscularly in healthy adults (18-49 yrs) at dosage levels of 10 mcg, 25 mcg, and 50 mcg. The secondary objective of this study is to assess the serum antibody responses to two doses of DCVC H1 HA mRNA Vaccine administered intramuscularly 28 days apart in healthy adults at dosage levels of 10 mcg, 25 mcg, and 50 mcg in comparison to a standard dose of IIV4.

Eligibility criteria: Inclusion Criteria:

1. Provide written informed consent prior to initiation of any study procedure.
2. Are able to understand and comply with planned study procedures and be available for all study visits.
3. Are males or non-pregnant, non-breastfeeding females, 18 to 49 years of age, inclusive at time of enrollment.
4. Must agree to collection of venous blood and nasal absorption specimens per protocol and enrollment in DMID 19-0025 biorepository protocol for use of residual blood specimens.
5. Are in good health\* and not have clinically significant medical, psychiatric, chronic or intermittent health conditions including those listed in Exclusion Criteria (Section 5.3) \*Refer to the protocol specific Manual of Procedures (Section 4.3) for this definition.
6. Does not have an ongoing symptomatic condition\* for which participant has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan.

   \*e.g., ongoing fatigue without a diagnosis for symptom.
7. Pulse is 50 to 100 beats per minute, inclusive.
8. Systolic blood pressure is 90 to 139 mmHg, inclusive.
9. Diastolic blood pressure is 55 to 89 mmHg, inclusive.
10. Body mass index (BMI) of 18 kilograms/square meter (kg/m\^2) to \<35 kg/m\^2 (inclusive) and weight \>/=110 lbs. at screening.
11. Women of childbearing potential\* must agree to use or have practiced true abstinence or use at least 1 acceptable primary form of contraception. \*\*

    * Not of child bearing potential - post-menopausal females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, salpingectomy, or Essure placement with history of documented radiological confirmation test at least 90 days after the procedure)
    * True abstinence is 100% of time no sexual intercourse (male's penis enters the female's vagina). (Periodic abstinence \[e.g. calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception).
    * Acceptable forms of primary contraception include monogamous relationship with a vasectomized partner who has been vasectomized for 180 days or more prior to the participant receiving the study product, tubal ligation, intrauterine devices, birth control pills, and injectable/implantable/insertable hormonal birth control products.
    * Must use at least one acceptable primary form of contraception or true abstinence for at least 30 days prior to receipt of study product and at least one acceptable primary form of contraception or true abstinence for at least 30 days following receipt of study product.
12. Women of childbearing potential\* must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours prior to each study vaccination.
13. Male participants receiving DCVC H1 HA mRNA Vaccine must agree to refrain from donating sperm and to use contraception until day 90 after last vaccination. \*\*

    * Acceptable contraception includes abstinence from intercourse with a female of childbearing potential or use of a male condom when engaging in any activity that allows for passage of ejaculate to a female during the intervention period for at least 90 days after last study vaccination.
    * Males in the immunogenicity comparator group do not have to refrain from sperm donation or abstain from intercourse or agree to use a male condom for purposes of this study.

Exclusion Criteria:

1. Have an acute illness\* or fever (body temperature \>/= 38.0°C/100.4°F), as determined by the site PI or appropriate sub-investigator, within 72 hours prior to study vaccination.

   \*An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the site PI or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol.
2. Have any medical disease or condition that, in the opinion of the site PI or appropriate sub-investigator, is a contraindication to study participation. \*\*

   \* Including acute, subacute, intermittent or chronic medical disease or condition that would place the participant at an unacceptable risk of injury, render the participant unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the participant's successful completion of this trial.
3. Has a screening laboratory\* \> Grade 1.

   \*White blood cell count, absolute neutrophil count, absolute lymphocyte count, hemoglobin, platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, creatinine, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, lipase
4. Has a positive urine toxicology screen (i.e., non-prescribed amphetamines, cocaine, and opiates).
5. ECG is deemed to be clinically significant\* by the PI or appropriate sub-investigator.

   \*ECG consistent with probable or possible myocarditis/pericarditis or demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results. An ECG that shows an average QTcF (Fridericia's correction) interval \>450 msec, complete left bundle branch block, signs of an acute or indeterminate-age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias.
6. Troponin (Troponin T, High Sensitivity) outside the laboratory normal range at screening.
7. Have any known or suspected immunosuppressive condition, acquired or congenital, or autoimmune conditions as determined by history and/or physical examination.
8. Have immunosuppression resulting from any treatment including a recent history (within 6 months prior to administration of study vaccine) or use of immunosuppressive or immune-modifying drugs.
9. Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior to study vaccination.
10. Have known active or recently active (12 months) neoplastic disease or a history of any hematologic malignancy. Non-melanoma, treated, skin cancers are permitted.
11. Have known human immunodeficiency virus, hepatitis B or hepatitis C infection at screening.
12. Have a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at screening.
13. Have known chronic liver disease, including fatty liver disease.
14. Have known hypersensitivity or allergy to any components of the study vaccine (including polyethylene glycol or egg protein).
15. Have a history of a severe reaction including allergic reaction following previous immunization with an investigational, authorized, or approved influenza vaccine or mRNA containing vaccine.
16. Have a history of Guillain-Barré Syndrome.
17. Have a known history of myocarditis, pericarditis, or myopericarditis.
18. Have a history of alcohol or drug abuse within 3 years prior to study vaccination.
19. Have any diagnosis, current or past, of schizophrenia, bipolar disease or other psychiatric diagnosis that may interfere\* with participant compliance or safety evaluations.

    \* As determined by the site PI or appropriate sub-investigator.
20. Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others within 5 years prior to study vaccination.
21. Have taken oral or parenteral (including intra-articular) corticosteroids of any dose within 30 days prior to study vaccination. Intranasal or topical (skin or eyes) corticosteroids are permitted.
22. Have taken high-dose inhaled or nebulized corticosteroids\* within 30 days prior to study vaccination.

    \* High-dose defined as per age as using inhaled high-dose per reference chart in the National Heart, Lung and Blood Institute Guidelines for the Diagnosis and Management of Asthma (EPR-3) or other lists published in UPTODATE
23. Have any significant disorder of coagulation requiring ongoing or intermittent treatment.
24. Have received any approved or authorized vaccines other than seasonal influenza vaccine within 60 days before enrollment.
25. Have received seasonal influenza vaccine within the 90 days prior to enrollment.
26. Have a known history of documented influenza infection with the past 90 days.
27. Have a history of receipt of an investigational H1 influenza vaccine within the past 10 years.
28. Received immunoglobulin and/or any blood products (except Rho D immunoglobulin) within the 90 days prior to study vaccination.
29. Received an experimental agent\* within 60 days prior to the study vaccination or are participating in another clinical trial with an interventional agent\*.

    * Including vaccine, drug, biologic, device, blood product, or medication.
    * Including licensed or unlicensed vaccine, drug, biologic, device, blood product, or medication.
30. The participant has any abnormality or permanent body art (eg, tattoo) that, in the opinion of the investigator, would obstruct the ability to observe local reactions at the injection site.
31. Donation of blood or blood products within 30 days prior to dosing.
32. Has had significant exposure to someone with SARS-CoV-2 infection or laboratory-confirmed influenza in the 14 days prior to screening or during the period between screening and enrollment visit\*.

    \* Defined by the CDC as a close contact with someone who has COVID-19.
33. Has had a positive SARS-CoV-2 test (home or laboratory-based) within 14 days prior to the screening visit or during the period between screening and enrollment visits.

Primary outcomes:
measure: Number and percentage of participants experiencing any adverse events of special interest (AESIs)
timeFrame: Day 1 through Day 394
measure: Number and percentage of participants experiencing any influenza like illnesses (ILI)
timeFrame: Day 1 through Day 394
measure: Number and percentage of participants experiencing any medically-attended adverse events (MAAEs)
timeFrame: Day 1 through Day 394
measure: Number and percentage of participants experiencing any new-onset chronic medical conditions (NOCMCs)
timeFrame: Day 1 through Day 394
measure: Number and percentage of participants experiencing any serious adverse events (SAEs)
timeFrame: Day 1 through Day 394
measure: Number and percentage of participants experiencing any unsolicited adverse events (AEs)
timeFrame: Day 1 through Day 57
measure: Number and percentage of participants experiencing solicited adverse events (AEs)
timeFrame: Day 1 through Day 42
measure: Number and percentage of participants with clinical laboratory adverse events (AEs)
timeFrame: Day 1 through Day 57
Secondary outcomes:
measure: Geometric mean fold rise (GMFR) in homologous H1-specific anti-stalk serum antibodies
timeFrame: Day 1 through Day 57
measure: Geometric mean fold rise (GMFR) in homologous H1-specific MN antibody
timeFrame: Day 1 through Day 57
measure: Geometric mean fold rise in homologous H1-specific HAI antibody
timeFrame: Day 1 through 57
measure: Geometric mean titers of homologous H1-specific anti-stalk serum antibodies
timeFrame: Day 1 through Day 57
measure: Geometric mean titers of homologous H1-specific hemagglutinin inhibition (HAI) antibodies
timeFrame: Day 1 through Day 57
measure: Geometric mean titers of homologous H1-specific microneutralization (MN) antibodies
timeFrame: Day 1 through Day 57
measure: Number and percentage of participants achieving HAI titer seroconversion against the homologous H1-specific hemagglutinin
timeFrame: Day 1 through 57
measure: Number and percentage of participants demonstrating HAI titer seroprotection against the homologous H1-specific hemagglutinin
timeFrame: Day 1 through 57
measure: The number and percentage of participants achieving MN titer seroconversion against the homologous H1-specific hemagglutinin
timeFrame: Day 1 through 57
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: University of Iowa - Infectious Disease Clinic
state: Iowa
Study officials:
References: